EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Luise Fischer iD, Nora Grieb iD, Uwe Platzbecker iD, Vladan Vucinic iD, Maximilian Merz iD

European Journal of Haematology · 2024-01 · 112 (1) · 19-27

DOI: 10.1111/ejh.14051 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 07.08.2023. Verfasst von Luise Fischer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, SpringWorks, Janssen-Cilag GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of chimeric antigen receptor (CAR) T cells revolutionized treatment of relapsed and refractory multiple myeloma (RRMM) in recent years. Currently, two CAR T cell products—idecabtagene vicleucel and ciltacabtagene autoleucel—are approved in the United States and the European Union to treat patients with three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti‐CD38 antibody. Moreover, seminal phase III trials of both agents in earlier lines of therapy have been published recently. Despite unprecedented rates of deep and lasting remissions in RRMM, there are still areas of uncertainty regarding the optimal use and distribution of CAR T cells in multiple myeloma. In the current review, we discuss the available data on approved CAR T cell products as well as unmet clinical needs and ongoing developments to optimize usage of this promising treatment modality in multiple myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansImmunotherapy, AdoptiveAntiviral AgentsMolecular Targeted TherapyProteasome Inhibitors

Stichwörter der Autor:innen

CAR T cellsCRSICANSciltacabtagene autoleucelidecabtagene vicleucelmultiple myelomarefractoryrelapsed

Substanzen

Antiviral AgentsProteasome Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany.
  • Innovation Center Computer Assisted Surgery (ICCAS), University of Leipzig, Leipzig, Germany.

ORCID-Profile: Luise Fischer, Nora Grieb, Uwe Platzbecker, Vladan Vucinic, Maximilian Merz

Förderung

  • Deutsche Forschungsgemeinschaft
  • SpringWorks
  • Janssen-Cilag GmbH
  • Springworks Therapeutics

Zitieren

APA

Fischer, L., Grieb, N., Platzbecker, U., Vucinic, V., & Merz, M. (2024). CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?. European Journal of Haematology, 112(1), 19-27. https://doi.org/10.1111/ejh.14051

Vancouver

Fischer L, Grieb N, Platzbecker U, Vucinic V, Merz M. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?. European Journal of Haematology. 2024;112(1):19-27. doi:10.1111/ejh.14051

BibTeX
@article{Fischer2024,
  author = {Fischer, Luise and Grieb, Nora and Platzbecker, Uwe and Vucinic, Vladan and Merz, Maximilian},
  title = {CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {112},
  number = {1},
  pages = {19--27},
  doi = {10.1111/ejh.14051}
}
Kostenlos starten →